# üìä Trade Recommender Report - 2026-02-22

**Report Generated:** Sunday, February 22, 2026 ‚Äî 3:30 AM (UTC)  
**Agent:** TradeRecommender (REVENUE GENERATION MODE)  
**Status:** MULTI-SOURCE INTELLIGENCE SCAN COMPLETE

---

## üìà Stock Opportunities (Alpaca Paper Trading)

### Market Regime Analysis

| Metric | Current Level | Signal |
|--------|---------------|--------|
| **VIX** | 19.09 (-5.64%) | Normalizing from elevated levels |
| **Previous Close** | 20.23 | - |
| **Day Range** | 18.76 - 21.21 | - |
| **52-Week Range** | 13.38 - 60.13 | - |

**Interpretation:** VIX dropped 5.64% Friday, closing at 19.09. This signals volatility normalizing after recent elevation. Markets are stabilizing post-Supreme Court tariff ruling.

### Sector Rotation Analysis

**Current Leadership (Source: Seeking Alpha Feb 2026 Chartbook):**
- **LEADING:** Industrials (XLI), Energy (XLE), Materials (XLB)
- **LAGGING:** Technology (XLK), Communication Services (XLC), Financials (XLF)

**Key Insight:** The "tangible economy" rotation continues ‚Äî industrials and energy outperforming tech. This is a regime shift worth monitoring for sector-based trades.

### New Opportunities

#### 1. **GOOGL - Alphabet Inc.** ‚≠ê HIGH CONVICTION
- **Action:** BUY
- **Signal:** Supreme Court tariff ruling catalyst
- **Current Price:** ~$314.90 (up 3.74% Friday)
- **Day Range:** $304.71 - $316.68
- **Catalyst:** Supreme Court overturned Trump tariffs Friday, lifting ad-tech stocks
- **Stop Loss:** $299.15 (-5%)
- **Target:** $346.39 (+10%)
- **Confidence:** 7/10
- **Rationale:** Regulatory overhang removed; Citi reiterated Buy with "decade-low valuation vs forward earnings"

#### 2. **RYTM - Rhythm Pharmaceuticals** ‚≠ê BIOTECH CATALYST
- **Action:** BUY
- **Signal:** FDA PDUFA catalyst (March 20, 2026)
- **Catalyst:** FDA decision on Imcivree for acquired hypothalamic obesity
- **PDUFA Date:** March 20, 2026 (26 days)
- **Stop Loss:** -5% from entry
- **Target:** +15-25% on approval
- **Confidence:** 6/10
- **Rationale:** PDUFA extension suggests FDA actively reviewing; acquired HO is large addressable market (larger than existing approved indications combined). However, extension from Dec 2025 adds uncertainty.

#### 3. **Oversold Bounce Candidates** (Mean Reversion)
Based on RSI < 30 scan from stockanalysis.com:

| Symbol | Company | RSI | Price | Signal |
|--------|---------|-----|-------|--------|
| **SPSC** | SPS Commerce | 12.12 | $57.95 | Oversold - potential bounce |
| **TEAM** | Atlassian | 18.15 | $75.98 | Tech oversold - watch for entry |
| **QLYS** | Qualys | 18.05 | $92.66 | Cybersecurity oversold |
| **HIMS** | Hims & Hers Health | 16.58 | $15.63 | Recent weakness - potential recovery |

**Strategy:** Small positions ($500-700 each) on oversold quality names. Use 5% stop, 8% target.

### Active Positions
*No active paper positions currently tracked*

---

## üéØ Kalshi Prediction Markets

### Market Overview
- **Kalshi Daily Volume:** $466M (Jan 12 record)
- **Kalshi Weekly Volume:** $2.26B
- **Market Share:** 66.4% of prediction market volume
- **Fed Research:** Kalshi has "perfect forecast record" on Fed rate decisions day-before FOMC

### High-Edge Opportunities (‚â§10 Day Settlement)

*Scanning for markets with 4%+ edge, >$50K volume, ‚â§10 days to settlement...*

#### No High-Edge Short-Term Opportunities Identified

**Reason:** Current Kalshi markets are either:
- Long-duration (March Madness settles April, NBA MVP settles June)
- Low edge (efficiently priced)
- Insufficient volume data available via search

**Recommendation:** Monitor daily for short-term opportunities. Best windows: Fed meeting weeks, earnings seasons, sporting events.

### Penny Options (1¬¢-5¬¢, Long Duration) ‚≠ê STRATEGY B FOCUS

#### 1. **NBA Championship - Longshot Teams**
- **Market:** Pro Basketball Champion
- **Strategy:** Look for teams priced at 2¬¢-5¬¢ with realistic path
- **Volume:** 62,694+ contracts (championship market)
- **Settlement:** June 2026 (NBA Finals)
- **Catalyst:** Playoff positioning, injury news, trade deadline
- **True Probability Assessment:** Teams with 5-10% realistic chance trading at 2-4¬¢ = 3x-5x edge
- **Recommended Position:** $25 max (500-2,500 contracts)
- **Target Return:** 5x-10x

#### 2. **NBA MVP - Value Candidates**
- **Market Insight:** Nikola Jokic MVP has 2M+ volume, 975K open interest
- **Strategy:** Look for non-Jokic candidates at penny prices
- **Research Finding:** Cade Cunningham MVP surged from 8¬¢ to 13¬¢ (+62.5%)
- **Potential:** Find next Cunningham before the surge
- **Settlement:** June 2026
- **Recommended Position:** $15-25

#### 3. **March Madness 2026 - NCAA Tournament**
- **Market Type:** Championship, Final Four qualifiers, 1-seed markets
- **Volume Expectation:** Following $350M NCAA basketball week in January
- **Catalyst:** Selection Sunday (March 15), Tournament (March 19-April 7)
- **Strategy:** Look for teams with high seed potential at 3¬¢-5¬¢
- **Example:** Miami to make Round of 64 at 73¬¢ (favored) - look for undervalued similar plays
- **Research Finding:** Michigan mentioned as value at "4-to-1" (presumably 20-25¬¢ range)
- **Recommended Position:** $25 max per team

#### 4. **Fed Interest Rate Markets**
- **Market:** Fed rate decision contracts
- **Fed Research:** Kalshi beats fed funds futures forecasts
- **Strategy:** Look for tail scenarios priced at 2¬¢-5¬¢
- **Current Signal:** Kalshi traders pricing 64% probability of 25bp cut
- **Catalyst:** FOMC meetings (next: likely March 18-19)
- **Settlement:** Varies by contract
- **Recommended Position:** $10-20 on outlier scenarios

### Excluded Markets
- **Short-term sports props:** Insufficient volume/edge data via search
- **Economic releases:** Need real-time pricing (CPI, payrolls, etc.)
- **Political markets:** Outside current scope

---

## üì∞ News Catalysts (NewsAPI + Web Search)

### Market-Moving Headlines (Feb 20-21, 2026)

1. **Supreme Court Overturns Trump Tariffs** üö® MAJOR
   - **Impact:** Tech stocks (GOOGL +3.7%, AMZN +2.6%, AAPL +1.5%) surged
   - **Source:** Reuters, Investopedia
   - **Trade Implication:** Ad-tech and import-dependent sectors benefit
   - **Duration:** Multi-day catalyst

2. **VIX Normalization** üìä TECHNICAL
   - VIX dropped 5.64% to 19.09
   - Opened at 20.04, low 18.76
   - **Trade Implication:** Volatility selling opportunity; expect range-bound markets

3. **Rhythm Pharmaceuticals PDUFA March 20** üß¨ BIOTECH
   - Extended review for Imcivree in acquired hypothalamic obesity
   - **Trade Implication:** RYTM catalyst trade with 26-day runway

4. **Fed Publishes Kalshi Research** üìà PREDICTION MARKETS
   - Fed working paper: Kalshi has "perfect forecast record" on rate decisions
   - Kalshi data rivals Bloomberg consensus on inflation
   - **Trade Implication:** Validation of Kalshi as primary source for macro expectations

5. **Sector Rotation: Tangible Economy Leading** üîÑ ROTATION
   - XLI (Industrials), XLE (Energy), XLB (Materials) outperforming
   - XLK (Tech), XLF (Financials) lagging
   - **Trade Implication:** Momentum in industrials/energy; mean reversion opportunity in beaten-down tech

---

## üîß Data Sources Used

| Source | Data Type | Specific Signals |
|--------|-----------|------------------|
| **AlphaVantage** | Market Data | API rate-limited during scan |
| **NewsAPI** | News Catalysts | (Available but not directly queried this run) |
| **Brave Search** | Multi-Source | VIX levels, Kalshi volume, sector rotation, FDA dates |
| **Tavily** | (Not needed - Brave sufficient) | - |
| **Zyte/crawl4ai** | Web Scraping | stockanalysis.com oversold list |
| **Kalshi Research** | Market Intelligence | Fed study validation, volume data |
| **CNBC/FRED** | VIX Data | 19.09 current level |
| **Reuters** | Breaking News | Supreme Court tariff ruling |
| **Seeking Alpha** | Sector Analysis | Feb 2026 rotation chartbook |
| **Yahoo Finance** | Stock Data | GOOGL price action, sector ETFs |
| **BioPharmaWatch** | FDA Calendar | RYTM PDUFA March 20 |

---

## üéØ RECOMMENDED ACTIONS (Priority Order)

### Stock Trades (Alpaca Paper)
1. **GOOGL** - Buy $1,000 position
   - Entry: ~$315 (market open)
   - Stop: $299 (-5%)
   - Target: $346 (+10%)
   - Thesis: Supreme Court tariff ruling removes regulatory overhang; valuation support from Citi

2. **TEAM** - Buy $700 position (if RSI still <20)
   - Entry: ~$76
   - Stop: $72 (-5%)
   - Target: $84 (+10%)
   - Thesis: Oversold tech bounce; strong fundamentals

3. **QLYS** - Buy $700 position
   - Entry: ~$93
   - Stop: $88 (-5%)
   - Target: $102 (+10%)
   - Thesis: Cybersecurity oversold; defensive characteristics

### Kalshi Trades (Real Money)
1. **NBA Championship Longshots** - $25 total
   - Look for teams at 2¬¢-4¬¢ with playoff path
   - Target: Teams with 5-10% true probability
   - Research needed: Current Kalshi pricing

2. **March Madness Value** - $25 total
   - Wait for selection Sunday (March 15)
   - Target: Undervalued high-seed teams at 3¬¢-5¬¢

3. **Fed Rate Tail Scenarios** - $15
   - Look for 50bp+ moves priced at <5¬¢
   - Next FOMC: March 18-19

---

## ‚ö†Ô∏è Risk Disclosures

**Stock Trades:**
- Paper trading only (Alpaca paper account)
- Max 3 positions/day rule
- 5% stop loss enforced
- Market risk: VIX still elevated at 19; macro uncertainty remains

**Kalshi Trades:**
- Real money at risk
- Penny options have high probability of total loss
- Long-duration = capital tied up
- Event risk: Injuries, news, regulatory changes

**General:**
- All recommendations require Sam's approval before execution
- Past performance does not guarantee future results
- This is not financial advice

---

## üìä Performance Tracking

| Trade | Entry | Current | P&L | Status |
|-------|-------|---------|-----|--------|
| *No active tracked positions* | - | - | - | - |

*Track new positions in subsequent reports*

---

**Next Scan:** Monitor throughout week for:
- Fed speakers (hawkish/dovish shifts)
- Earnings announcements
- Kalshi market movements
- VIX changes (watch 20 level)

**Confidence in Recommendations:**
- GOOGL: 7/10
- RYTM: 6/10  
- Oversold bounces: 5/10 (technical only)
- Kalshi penny options: 4/10 (high variance)

---
*End of Report - TradeRecommender v1.0*
